Mayzent is manufactured by Novartis [1].
Who else makes Mayzent?
As of now, Novartis is the sole manufacturer of Mayzent [1].
What is Mayzent used for?
Mayzent is a medication approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults [2]. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [2].
When did Mayzent get approved?
The U.S. Food and Drug Administration (FDA) approved Mayzent in March 2020 [2].
How does Mayzent work?
Mayzent is a sphingosine 1-phosphate (S1P) receptor modulator [3]. It works by trapping certain types of white blood cells, called lymphocytes, in the lymph nodes [3]. This action prevents these lymphocytes from entering the central nervous system, where they can contribute to nerve damage in MS [3].
What are the potential side effects of Mayzent?
Common side effects of Mayzent can include upper respiratory tract infections, headache, and nausea [2]. More serious side effects can occur, such as a slow heart rate (bradycardia), liver enzyme elevations, and vision problems [2]. Patients should discuss potential risks with their healthcare provider.
What is the patent status for Mayzent?
Information regarding the specific patents for Mayzent and their expiration dates can be found on resources like DrugPatentWatch.com [4].
How does Mayzent compare to other MS treatments?
Mayzent is one of several disease-modifying therapies available for relapsing forms of MS. Other treatments may include injectable medications or other oral medications that work through different mechanisms [5]. The choice of treatment depends on individual patient factors and physician recommendations.